Technology | Contrast Media | October 04, 2016

GE Healthcare Announces FDA Labeling Change for Optison Ultrasound Contrast Agent

Administration has removed contraindication for use in patients with cardiac shunts and for administration by intra-arterial injection

GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection

October 4, 2016 — GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound contrast agent Optison (Perflutren protein-Type A Microspheres Injectable Suspension, USP). The FDA removed the contraindications for use in patients with cardiac shunts and for administration by intra-arterial injection. Both contraindications have been revised and moved to the WARNINGS AND PRECAUTIONS section (5.3 : Systemic Embolization) of the Full Prescribing Information.

Optison is the first contrast agent available in the United States to receive this contraindication label change.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal flow of the circulatory system. Previously, in suspected cardiac shunt populations, an agitated saline procedure was needed to determine if a shunt existed and whether the patient was contraindicated to receive an ultrasound contrast agent.

Sharon L. Mulvagh, M.D., professor of medicine, Women's Heart Clinic director, associate director, preventive cardiology consultant in cardiovascular diseases, Mayo Clinic and Mayo Clinic College of Medicine, said: "I am very pleased that the FDA has approved the removal of the cardiac shunt contraindication from the ultrasound contrast agent Optison. This label change will allow more patients access to a diagnostic imaging tool that has established safety and efficacy. The FDA’s decision to remove this contraindication is supported by a body of data from studies demonstrating safety and clinical benefits of all ultrasound contrast agents in patients with cardiovascular diseases.”

She added: “This is an important step forward in eliminating barriers to ultrasound contrast use and delivering quality diagnostic care of value to our patients.”

Steven Feinstein, M.D., co-president of the International Contrast Ultrasound Society, said: “Up to one-third of our patients have known or suspected cardiac shunts and, thanks to this important FDA decision, they too will now have access to ultrasound contrast agents, which offer an inexpensive and radiation-free option for diagnostic imaging. The International Contrast Ultrasound Society applauds the FDA for its decision, and believes it will benefit individual patients as well as our healthcare delivery system.”

Jonathan Lindner, M.D., M. Lowell Edwards Professor of Cardiology at the Knight Cardiovascular Center, Oregon Health & Science University, said: “Thanks to the overwhelming weight of evidence from clinical trials, most practitioners in the field of echocardiography already realize the benefits of using contrast agents and understand their capacity to improve diagnostic accuracy, improve outcomes and streamline care. However, a major obstacle to widespread use has been lack of consensus and confusion regarding how far one needs to go to exclude shunts, no matter how small. The decision by the FDA removes a barrier to using this contrast agent, and may result in an increase in the number of labs that will choose to utilize this important technology, which allows clinicians to provide the best care possible.”

For more information: www.gehealthcare.com

Related Content

EchoGo uses AI to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

EchoGo uses artificial intelligence (AI) to calculate cardiac ultrasound left ventricular ejection fraction (EF), the most frequently used measurement of heart function, left ventricular volumes (LV) and, for the first time for an AI application, automated cardiac strain.

News | Cardiovascular Ultrasound | November 14, 2019
November 14, 2019 — Ultromics has received 510(k) clearance from the U.S.
Global Echocardiography Normal Values Study Presented at European Society of Cardiology Congress
News | Cardiovascular Ultrasound | September 04, 2019
September 4, 2019 — Final data from the World Alliance Societies of Echocardiography (WASE) Normal Values...
Terason Partners With DiA Imaging Analysis for Point-of-care Cardiac Ultrasound AI
News | Cardiovascular Ultrasound | August 26, 2019
Ultrasound imaging company Terason has partnered with DiA Imaging Analysis, provider of artificial intelligence (AI)-...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
360 Photos | Cardiovascular Ultrasound | July 11, 2019
This is a 360 degree view of a live cardiac echo demonstration for the Siemens Healthineers Acuson SC2000 ...
ASE 2019 virtual reality demonstration with TomTec which showed hot VR can be used to review complex 3-D anatomy and make more accurate measurements on cardiac imaging.

A virtual reality demonstration by TomTec, showing how VR can be used to review complex 3-D anatomy and make more accurate measurements on cardiac imaging.

Feature | Cardiovascular Ultrasound | July 10, 2019 | Dave Fornell, Editor
Here is an overview of the hot topics and new technology trends in cardiovascular ultrasound from the 2019 American S
Videos | Cardiovascular Ultrasound | July 10, 2019
This is an example of a cardiac echocardiography exam performed using an iPhone and the Butterfly IQ ultrasound trans
360 Photos | Cardiovascular Ultrasound | July 10, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
360 Photos | Cardiovascular Ultrasound | July 10, 2019
This 360 degree photo shows a basic, point-of-care cardiac echocardiogram being performed using a smartphone turned i
360 Photos | Cardiovascular Ultrasound | July 09, 2019
A view of a mitral valve on a GE Healthcare Vivid E95...
Overlay Init